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ABSTRACT 
Objective: A simple, sensitive and rapid LC-MS/MS technique was developed for the quantitation of trandolapril (TDL) and verapamil (VPL) in a 
biological matrix and validated. 
Methods: Sample preparation processed by SPE (Solid Phase extraction) on phenomenex cartridge using Ledipasvir as an internal standard. Two 
drugs were eluted on waters symmetry-RP18 
Results: The quantification approach was validated in 5-1500 ng/ml linear concentration range for TDL and 1-2000 ng/ml for VPL. The intraday 
and inter-day precision and accuracy were found to be 0.58% to 5.69% and 93% to 104% for two drugs. The average recoveries for TDL and VPL 
were found to be 92.9% and 93.5% respectively.  
(5µ, 150 mm×4.0 mm) column with the mobile composition of 10 mmol ammonium formate and 
ACN(acetonitrile) in the ratio of 70:30 %V/V. Detection and quantitation were processed by electrospray ionization in positive ionization mode. 
Conclusion: The developed work was validated and can be applicable to the routine analysis of TDL and VPL simultaneously in a biological matrix.  
Keywords: Trandolapril, Verapamil, Cancer, ACE inhibitor, Accuracy, LC-MS/MS, Validation 




TDL is a nonsulfhydryl prodrug that is de-esterified to trandolaprilat 
in the liver, belongs to the class of an angiotensin-converting 
enzyme (ACE) inhibitor medications [1]. It obstructs ACE, which 
shows a significant role in the conversion of angiotensin-I (AT-I) to 
angiotensin-II (AT-II). AT-II controls blood pressure and is a main 
constituent of the RASS (renin-angiotensin aldosterone system) [2]. 
It helpful in hypertension treatment and increase survival 
subsequent myocardial infarction patients suffering from left 
ventricular dysfunction. It acts as an adjunct in heart failure and 
reduces the rate of progress of the renal disease in patients with 
hypertension, diabetes and overt nephropathy. It chemically 
designated as (2S, 3aR, 7aS)-1-[(2S)-2-{[(2S)-1–ethoxy-1-oxo-4–
phenylbutan-2-yl] amino} propanol]–octahydro-1H–indole-2-
carboxylic acid [3, 4]. 
 
 
Fig. 1: Structure of trandolapril 
 
VPL is useful in the treatment of high blood pressure by dilating the 
blood vessels, angina by increasing the oxygen and blood supply to 
the heart and supraventricular tachycardia. It also useful in the 
prevention of a migraine and cluster headaches. The drug was 
administered either by oral route or through injection into a vein. It 
acts by blocking the voltage-dependent calcium channel and this 
drug considered as a class-IV antiarrhythmic agent in cardiac 
pharmacology [4, 5]. IUPAC name of the compound was (RS)-2-(3, 4-
Dimethoxyphenyl)-5-{[2-(3, 4–dimethoxyphenyl) ethyl]-(methyl) 
amino}-2–prop-2-yl pentanenitrile [4, 6]. Chest pain is controlled by 
using verapamil regularly. 
 
 
Fig. 2: Structure of verapamil 
 
Literature survey of TDL and VPL revealed that several analytical 
techniques were employed such as high-performance thin layer 
chromatography (HPTLC) [7], high-performance liquid chromatography 
(HPLC) [8-12] and LC-MS/MS [13, 14]. Aim of the present work was 
to develop an improved, accurate and rapid LC-MS/MS technique 
with low retention time. 
MATERIALS AND METHODS 
Chemicals and reagents 
The TDL, VPL reference standards and internal standard 
(Ledipasvir) were obtained from Hetero drugs, Hyderabad. HPLC-
grade ACN and methanol were procured form SD-Fine Chemicals, 
Mumbai, India. Phenomenex SPE-cartridges were bought from 
Phenomenex, Bengaluru, India. Analytical grade ammonium formate 
and formic acid were bought from Qualigens chemicals, Mumbai, 
India. 
Mass spectrometric and liquid chromatographic conditions 
Liquid chromatographic system (Shimadzu, Japan) consisted of a 
binary LC-20A CE pump, solvent degasifying system (DGU-20A), 
autosampler (SIL-HTC) and temperature controller (CTO-10 AS) for 
maintaining column temperature was used for the chromatographic 
elution of the two drugs and internal standard (IS). Separation of 
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analyte peaks was carried out with Waters symmetry-RP18 
Mass spectrometric detection was processed using API-4000 mass 
spectrometer (MDS-SCIEX, Toronto, Canada) combined with ESI 
(electrospray ionization). The MRM transitions for the quantitation 
of TDL, VPL and Ledipasvir were m/z 431.2/234.1, m/z 455.0/165.0 
and m/z 889.4/130.0 respectively. The optimized mass parameters 
like ion-spray voltage, curtain gas, Gas-1, Gas-2, collisional activation 
dissociation, and turbo heater temperature were processed at 2500 
V, 30 psi, 40 psi, 65 psi, 8 psi and 450 °C respectively. The 
parameters depends on the compound, namely declustering 
potential(DP), entrance potential, collision cell exit potential (CEP) 
and collision energy were adjusted to 90 V, 9 V, 12 V and 25 V for 
TDL and 80 V, 9 V, 10 V and 25 V for VPL respectively. 
(150 
mm×4.0 mm, 5µ) column at 40 °C oven temperature with the mobile 
composition of ACN and 10 mmol ammonium formate in the ratio of 
70:30 v/v. The mobile phase flow of 0.9 ml/min was processed 
through an analytical column with 5 °C autosampler temperature. 
Quality and calibration control samples 
TDL and VPL stock solutions (200 µg/ml) were freshly processed by 
dissolving accurate quantities of drugs in methanol as solvent 
separately. The quality control (QC) samples and calibration 
standards (CS) were processed by spiking with suitable volumes of 
working standard solutions made from intermediate stocks for the 
two drugs to blank plasma. The QC concentrations for TDL/VPL 
were LLOQ (lower limit of quantification): 5/1 ng/ml, Low QC (low-
quality control): 10/2 ng/ml, Medium QC (medium-quality control): 
600/600 ng/ml and High QC (high-quality control): 1100/1500 
ng/ml. The CSs were 5, 10, 150, 300, 400, 600, 850, 1100 and 1500 
ng/ml for TDL and 1, 2, 40, 200, 350, 600, 900, 1500 and 2000 
ng/ml for VPL. Ledipasvir (LPR) 100 µg/ml stock solution was 
prepared by dissloving an accurate amount of IS in methanol. LPR 8 
µg/ml working standard was made from 50% methanol. Standard 
and stock sample solutions were kept at 2 to 8 °C and QC standards 
and CSs were kept at-70 °C till actual sample analysis. 
Preparation of sample solution 
Prior to the separation, all samples subjected for freezing, QCs and 
CSs sample concentrations were equilibrated to room temperature. 
To 250 µl of spiked sample, 50 µl of LPR was mixed and subjected to 
vortex for 30 sec. Further 150 µl of buffer (10 mmol ammonium 
formate pH 3.2) was added and placed in a centrifuge for 15 min at 
4500 rpm. Further samples were processed through pre-treated 
phenomenex cartridges with methanol and 10 mmol ammonium 
formate buffer. The sample matrix was exhausted out from the 
cartridges by the application of positive pressure (nitrogen). The 
cartridges were cleaned with 1 ml of 10 mmol ammonium formate 
buffer and 1 ml of 50% methanol. The IS and drugs were separated 
with 500 µl of the mobile phase into pre-labeled vials. 
System suitability and sensitivity 
System suitability experimentation was executed by introducing six 
repeated injections, using an extracted sample of TDL/VPL and internal 
standard at the starting of each lot. Analytical technique selectivity was 
analysed for potential interfering matrix components in 10 different 
sources (6 Na-heparinized, 2-haemolysed and 2-lipemic) of blank 
plasma sample by extraction and examination of the resultant 
chromatograms for interfering matrix components peaks [15-18]. 
Analytes stock solutions were processed by dissolving required quantity 
in methanol. Working solutions were processed in 50 % methanol and 5 
µl was introduced in to the system to check for possible interfering 
constituents at the elution time of the drugs and IS. 
Accuracy and precision 
Intra-day accuracy and precision were evaluated by identical analysis of 
samples on the same day. The sample runs consist of calibration 
standards and 6 replicates of LLOQ, Lower-QC, Medium-QC, and High-QC 
samples. The inter-day accuracy and precision were evaluated by 
determination of 3 accuracy and precision lots on three di fferent days 
[19-21]. The % CV at each sample concentration should be<15%. 
Similarly, an average accuracy should be between 85%–115% all and for 
LLOQ it should be 80%–120% of the nominal concentration. 
Linearity and re-injection reproducibility 
The five calibration curve lines were plotted by preparing and analysing 
9 different concentration solutions for the estimation of linearity. Linear 
(1/x2
Method ruggedness 
), least squares regression algorithm was used to construct linearity 
plot from the data of peak response ratio (analyte/IS) versus 
concentration. The linearity formula was used to estimate the projected 
concentrations in samples within the analytical runs. The correlation 
coefficient of calibration curves should to be more than 0.99 for the two 
analytes [16]. Re-injection reproducibility estimated for extraction 
samples by re-injecting the sample after storing at 5 °C. 
To find out method ruggedness of analytes, two lots were studied for 
accuracy and precision. The first lot was assessed on two Symmetry-
ShieldRP18
Carryover effect 
-(150 mm×3.9 mm, 5 µm) analytical columns with 
different batch numbers and the second lot was studied by two 
different analysts. 
Carryover effect was assessed to confirm that the washing solution 
used to clean the infusing needle and the port is able to evade any 
carry forward of an introduced sample in preceding runs. 
Autosampler carryover was estimated by consecutively introducing 
extracted blank plasma, duplicate LLOQ, duplicate ULOQ sample 
followed by introducing duplicate blank plasma. Cross selectivity 
test was executed to check the conversion of TDL to VPL and vice 
versa during successive steps of analysis [14]. This test was 
performed at LLOQ and HQC levels for both the analytes in duplicate 
and processed along with two blank plasma samples.  
Matrix effect and Recovery 
Extraction retrieval of the drugs and IS from biological matrix was 
assessed in six duplicates by comparing the maverage peak 
responses of pre-extraction fortified samples to those of post -
extraction fortified samples. Absolute matrix effect was evaluated by 
paralleling the average peak responses of post-extraction fortified 
samples to those of neat samples prepared in elution solution. To 
evaluate the relative matrix effect in different plasma lots, post -
extraction fortified samples were prepared in duplicate at Low-QC 
and High-QC concentrations and % CV was assessed. Effect of matrix 
ions on drugs sensitivity were estimated by analyte infusion [13]. 
Briefly, TDL, VPL and Ledipasvir (at ULOQ level) standard solution 
was injected post-column through the mobile phase having infusion 
pump. 5 µl aliquots of extracted control samples were then infused 
into the column and anlyte chromatograms were estimated. 
Stability assessment 
TDL and VPL stock solutions and IS were tested at room conditions 
(short-term stability at 25 °C) and at 5 °C (long-term stability). Stability 
findings were estimated by determining the peak area (analyte/IS) of 
samples against freshly processed samples with same concentration. 
The % difference should be±10% for both stability solutions. Freeze-
thaw (at −70  °C) stability, bench-top stability, autosampler (at 5 °C) 
stability, processed sample (at 25 °C) stability and long term (at −70 °C) 
stability were processed at Low-QC and High-QC levels using 6 
replicates. The stability solutions were estimated against freshly 
processed calibration standards [22-24]. 
Dilution integrity 
It was processed to validate the test for dilution, performed on higher 
concentrations of analyte (above ULOQ). It was processed at 1.6 times 
the ULOQ concentration and 6 duplicate samples of ¼ and ½ 
concentrations were processed. The concentrations were estimated by 
the application of dilution factor 4 and 2 respectively by comparing with 
the freshly processed calibration standards [15, 16]. 
RESULTS AND DISCUSSION 
Method development 
Present method was projected to improve upon the existing 
methods in order to achieve higher sensitivity, lower sample volume 
requirement for extraction and use of Ledipasvir internal standard 
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for better precision and accuracy. Moreover, none of the reported 
method afforded baseline chromatographic separation of TDL and 
VPL under the established chromatographic conditions. Both TDL 
and VPL were processed in the positive mode and the ions of 
precursor and product were optimized for two drugs and ledipasvir 
150 ng/ml solutions by injecting in mass range of 50–500 Da. The Q-
1 full scan for two drugs and ledipasvir primarily contains 
protonated precursor [M+H]+ ions at m/m/z431.2, 455.0 and 889.4 
for TDL, VPL and IS respectively. The corresponding stable and 
abundant productions in Q-3 MS were detected at m/z 234.1, 165.0 
and 130.0 respectively. The MRM transitions for the quantification 
of TDL, VPL and IS were m/z431.2/234.1, m/z 455.0/165.0 and m/z 
889.4/130.0 respectively. The chromatographic parameters were 
optimized to increase peak response and reduce the interference of 
impurity peaks. In order to achieve this, several reversed-phase 
columns like Hypersil-Gold (5 µ, 150 mm × 4.6 mm), Hypurity-
Advance (5 µ, 150 mm × 4.6 mm), BDS Hypersil-C18 (5 µ, 150 mm × 
4.6 mm) and symmetry-RP18 (5µ, 150 mm×4.0 mm) column were 
verified using similar mobile phase. All four columns afforded 
chromatographic elution of the analytes but the response was not 
adequate especially at the LLOQ levels of TDL and VPL. However, the 
signal intensity of the drugs were fairly high on Symmetry Shield-
RP18
 
 column compared to other columns, with comparatively less 
peak tailing in VPL. Further optimization was made by the change in 
the aqueous/organic ratios of the mobile phase using the same 
column. Increase in the organic phase (>70%) result in improper 
peak shapes, while ratio at 50:50 %V/V the elution time was more 
than 4.0 min. Mobile phase with 10 mmol ammonium formate and 
ACN in a proportion of 30:70 %V/V produce symmetric peaks, 
better retention and good peak response with less matrix effect. 
 
Fig. 3: Typical chromatograms of A) Double blank plasma B) Blank plasma with IS C) TDL, VPL at LLOQ level with IS  
 
It was necessary to have the chromatographic analysis time of 4.0 
min for higher sensitivity and better ionization efficiency.  The 
chromatograms in fig. 3A-C showed no interference with an elution 
time of TDL and VPL against endogenous components. However, as 
they eluted much ahead of VPL there was no interference in the 
quantitation and no further attempt was made towards their 
identification. The resolution factor between the analytes under the 
established conditions was 3.8, while the capacity factors for TDL 
and VPL were 2.01 and 0.93, respectively. Further, there was no 
nosiness of medications at the elution time of the two drugs. Post-
column injection chromatograms showed the lake of matrix effects 
with no signal improvement or suppression at TDL and VPL 
retention times (fig. 3). 
Protein precipitation and liquid-liquid extraction methods were not 
providing precise and accurate results. As a result, Solid-phase 
extraction was processed on different separation cartridges, namely 
Bond Elut C18
Method validation results 
, Oasis-HLB, Phenomenex Strata-X, and Lichrosep-DVB. 
It was found that the addition of 2 mmol ammonium formate buffer 
was essential during all stages of workup to obtain adequate 
response and consistency in the recovery with minimal matrix 
interference. The extracts found with Phenomenex cartridges were 
cleaner than remaining cartridges [13, 14].  
The % CV values for system suitability were obtained between 
0.09% to 0.32 % for the elution times and 0.52% to 1.57% for the 
peak response of two analytes and internal reference standard. For 
the determination of selectivity, the response for 10 different blank 
plasma lots at the elution times of analytes was equated with the 
peak response (at LLOQ). None of the blank plasma sources 
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exhibited any obvious interference (≤0.52% of LLOQ sample for TDL 
and VPL) at elution times of analytes. 
The method was evaluated for carryover for column and auto-
sampler with blank plasma after consequent infusion of ULOQ of 
analytes and the findings were ≤0.64%. Peak response ratios 
(analyte/IS) against the sample concentrations were plotted to 
calculate linear regression. The linear curves were obtained over 5-
1500 ng/ml range for TDL and 1-2000 ng/ml range for VPL. The 
corresponding regression equations for TDL and VPL were y = 
(0.00089±0.00002) x+(0.00052±0.00021) and y=(0.00025 
±0.00010) x+(0.00038±0.00008) respectively, with a correlation 
coefficient (r2
 
) of ≥ 0.9994. For both the analytes, the bias of back-
calculated values in calibration range was within 7.6% of the 
nominal concentration values. The signal-to-noise ratio at the LLOQ 
concentration was ≥ 15 and ≥  29 for TDL and VPL respectively. The 
inter and intraday precision and accuracy findings were tabulated in 
table 1. The relative standard deviations were ≤ 5.69% and the 
overall mean accuracy ranged from 93.00% to 104.00% for the two 
drugs. 
Table 1: Trandolapril and verapamil data for intra and inter-day precision and accuracy 
Nominal concentration (ng/ml) Intra-day Inter-day 
Accuracy (%) %RSD Accuracy (%) %RSD 
Trandolapril      
5 103.6 1.23 103.2 5.67 
10 93.2 4.9 97.1 5.2 
600 103.2 3.5 103.2 4.2 
1100 103.6 7.9 102.9 2.9 
Verapamil      
1 104.5 5.2 107.5 5.1 
2 94.2 3.2 93.6 4.21 
600 98.2 4.8 94.6 5.1 
1500 95.9 0.59 95.1 0.92 
 
Table 2: Trandolapril and verapamil data for extraction recovery 
Analyte and QC levels peak response  Extraction recovery 




Trandolapril     
LQC 36525 37526 97.33 
MQC 378455 365214 103.63 
HQC 10005236 10506345 95.23 
Verapamil     
LQC 35568 37523 94.79 
MQC 543985 532852 102.09 
HQC 5263521 5405892 97.37 
Ledipasvir    
LQC 925345 945852 97.83 
MQC 935621 975623 95.89 
HQC 945654 986521 95.86 
 
Table 3: Matrix effect data for trandolapril and verapamil 
Analytes/IS 
 
Average area response (n = 6) Neat samples in elution solution (B) Matrix factor (A/B) 
Post-extraction spiking (A) 
LQC HQC LQC HQC LQC HQC 
Trandolapril  45615 13025468 46523 14086955 0.9804828 0.924648 
Verapamil  46750 6486531 48523 6542586 0.9634606 0.991432 
Ledipasvir 1045263 1203564 1123758 1305462 0.9301496 0.921945 
 
Table 4: Stability data for trandolapril and verapamil 
Storage condition QC level Accuracy (%) Precision (% CV) 
TDL VPL TDL VPL 
Bench-top stability 
(8 h, 25 °C) 
LQC 35.14 98.23 1.25 2.01 
HQC 95.65 95.23 0.52 1.3 
Freeze-thaw stability 
(at −70 °C, 5cycles) 
LQC 94.57 94.95 1.52 1.52 
HQC 96.12 96.24 0.98 0.35 
Auto-sampler stability 
(74 h, 5 °C) 
LQC 94.21 97.84 0.58 0.84 
HQC 95.32 95.69 0.89 0.98 
Processed sample 
 stability (16 h, 25 °C) 
LQC 94.68 98.23 0.68 0.74 
HQC 98.41 97.46 1.35 0.25 
Long-term stability (at −70 °C for 116 d,) LQC 97.25 96.58 1.25 0.26 
HQC 97.66 97.32 0.36 1.25 
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The average recoveries for TDL and VPL were found to be 92.9% and 
93.5% respectively (table 2). The average recovery of the internal 
standard was 90.87%. These findings specifies the developed 
technique was improbable to be modified by intra or inter-individual 
differences in the biomatrix and that the technique has good accuracy 
and reproducibility. The e ffects of matrix components suppression or 
improvement, represented as IS normalized matrix effects, ranged 
from 0.965 to 1.245 for both the analytes (table 3). The % CV findings 
for relative matrix effect in lipemic, sodium-heparin plasma and 
haemolysed plasma lots also represents that no ion improvement or 
suppression of the analytes (intensities) (table 2). 
The TDL and VPL stock solutions and ledipasvir were stable in 
methanol at refrigerated and room conditions for 2 w and 24 h 
respectively. The bench top stability of analytes in plasma were 
proven up to 8 h. Both the analytes were stable during 5 freeze-thaw 
cycles and for at least 74 h in the autosampler. Processed sample 
stability of the analytes was established up to 16 h at 25 °C with no 
obvious difference in the concentration of TDL and VPL. The long-
term stability (at-70 °C) samples were stable for 116 d and findings 
were tabulated in table 4.  
Precision and accuracy results obtained in order to establish method 
ruggedness with different RP-columns and different analysts were 
ranged from 0.83% to 4.25% and 97.60% to 98.37%, respectively 
for TDL and VPL. Likewise, the % CV and accuracy for dilution 
reliability of ½ and ¼th dilution varied from 1.67% to 3.27% and 
95.6% to 99.25%, respectively for two drugs. 
CONCLUSION  
An LC–MS/MS technique was developed for the sensitive and 
specific determination of trandolapril and verapamil in human 
plasma and validated using the ledipasvir internal reference 
standard. There was no interference or matrix effect from 
endogenous substances in the quantitative analysis. The calibration 
range established for TDL and VPL was adequate using a small 
sample volume for the analysis. The optimized SPE protocol gave 
highly precise and consistent recovery for the two analytes with no 
further stages of dehydration and reconstitution. 
AUTHORS CONTRIBUTIONS 
All the author have contributed equally 
CONFLICT OF INTERESTS  
Declared none 
REFERENCES 
1. Berl T. Review: renal protection by inhibition of the renin-
angiotensin-aldosterone system. J Renin Angiotensin 
Aldosterone Syst 2009;10:1-8. 
2. Diaz A, Ducharme A. Update on the use of trandolapril in the 
management of cardiovascular disorders. Vasc Health Risk 
Manag 2008;4:1147-58. 
3. Guay DR. Trandolapril: a newer angiotensin-converting 
enzyme inhibitor. Clin Ther 2003;25:713-75. 
4. Reynolds NA, Wagstaff AJ, Keam SJ. Trandolapril/verapamil 
sustained release: a review of its use in the treatment of 
essential hypertension. Drugs 2005;65:1893-914. 
5. 
6. 
Tfelt-Hansen PC, Jensen RH. Management of a cluster 
headache. CNS Drugs 2012;26:571–80.  
7. 
Merison K, Jacobs H. Diagnosis and treatment of a childhood 
migraine. Curr Treatment Options Neurol 2016;18:48. 
Sreekanth N. HPTLC method development and validation of 
trandolapril in bulk and pharmaceutical dosage forms. J Adv 
Pharma Technol Res 2010;
8. 
1:172-9. 
Tapas Kumar Laha, Lopamudra Adhikari. RP-HPLC analysis of 
trandolapril in pharmaceutical dosage forms. Asian J Chem 
2008;20:352-6
9. Ganipisetty LA, Dachinamoorthy D. Stability indicating RP-
HPLC method development and validation of simultaneous 
estimation of trandolapril and verapamil hydrochloride with 
forced degradation studies in bulk and commercial products. 
Int J Pharma Res Scholars 2015;4:1-9.  
. 
10. Tejashwi E, Kiran Kumar S, Siddartha B. Simultaneous 
estimation and validation of Trandolapril and Verapamil in 
bulk and pharmaceutical dosage form by RP-HPLC method. 
World J Pharm Pharm Sci 2014;3:652-62. 
11. Laxmi Madhuri P, Vusuvandla Geetha. Development and 
validation of RP-HPLC method for the simultaneous estimation 
of verapamil hydrochloride and Trandolapril in bulk and 
pharmaceutical dosage forms. Asian J Pharm Anal Med Chem 
2016;4:38-46. 
12. Senem Sanli, Nurullah Sanli. Development and validation of a 
liquid chromatographic method for the concurrent assay of 
weakly basic drug verapamil and amphoteric drug trandolapril 




Irene Panderi, Constantinos Pistos. Liquid chromatographic 
tandem mass spectrometric determination of trandolapril in 
human plasma. Anal Chim Acta 2005;
14. 
540:375-82. 
Naser Altannak, Ahmad Hemdan. UPLC-QToF-MS analysis of 
trandolapril and verapamil in the dosage form and spiked 
human plasma using solid phase extraction: stability indicating 
assay method. Curr Pharma Anal 2017;13
15. US FDA, Guidance for industry bioanalytical method validation, 
food and drug administration, the center for drug evaluation 
and research (CDER), Rockville, Maryland, USA; 2001.  
:450-8. 
16. Anggun Aji Mukti, Fathul Jannah, Arief Nurrochmad, Endang 
Lukitaningsih. Development and validation method for 
quantitative determination of ciprofloxacin in human plasma 
and its application in bioequivalence test. Asian J Pharm Clin 
Res 2016;9:89-95. 
17. Atul Vasanth D, Rajkamal B. A UPLC-MS/MS method 
development and validation for the estimation of 
pomalidomide from human plasma. Int J Appl Pharm 2017; 
9:37-43.  
18. International Conference on Harmonization (ICH) of Technical 
Requirements for the Registration of Pharmaceuticals for 
Human Use, Validation of analytical procedures: Methodology, 
ICH-Q2B, Geneva; 1996. 
19. Validation of Analytical Procedures: Methodology. ICH 
Harmonised Tripartite Guidelines; 1995. 
20. Marlina Ika, Rizka Andalusia, Supandi Supandi, Yahdiana 
Harahap. Simultaneous analytical method development of 6-
mercaptopurine and 6-methylmercaptopurine in dried blood 
spot using ultra performance liquid chromatography-tandem 
mass spectrometry. Int J Appl Pharm 2017;9:168-71.  
21. Birva A Athavia, Zarna R Dedania, Ronak R Dedania, Vijayendra 
Swamy SM, Chetana B Prajapati. Stability indicating HPLC 
method for determination of vilazodone hydrochloride. Int J 
Curr Pharm Res 2017;9:123-9. 
22. Wani TA. 
23. Brian Kiesel. LC-MS/MS assay for the quantitation of the 
tyrosine kinase inhibitor neratinib in human plasma. J Pharm 
Biomed Anal 2017;134:130-6.  
Ultra performance liquid chromatography-tandem 
mass spectrometric method development and validation for 
determination of neratinib in human plasma. South Afr J Chem 
2015;68:113-25.  
24. Tijare LK, Rangari NT, Mahajan UN. A review on bioanalytical 
method development and validation. Asian J Pharm Clin Res 
2016;9:6-10.
 
